Amgen Inc. (AMGN) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General
Amgen Inc. (AMGN) Profile & Business Summary
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Key Information
| Ticker | AMGN |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.amgen.com |
Market Trend Overview for AMGN
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-08-17 (ET)
As of 2026-08-17, AMGN is in a strong upward move. Over the longer term, the trend remains bullish.
AMGN last closed at 419.38. The price is about 1.5 ATR above its recent average price (406.56), and the market is currently in a strong upward move. Price at 419.38 is holding above minor support near 375.96. If price continues higher, it may face minor resistance around 421.79. View Support & Resistance from Options
The trend is still positive, but signs of slowing momentum suggest growing two-sided risk.
Trend score: 95 out of 100. Overall alignment is strong. The market is currently in a strong and established uptrend. Trend signals are well aligned across timeframes, suggesting a stable and consistent trend.
A key downside risk boundary is near 362.93. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-06-25, reflecting a technical shift toward positive directional alignment.
[2026-08-07] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Closing activity showed limited conviction and did not suggest strong overnight positioning.
As of 2026-08-10, price has extended significantly above its primary volume area, entering a liquidity-thin zone. While the uptrend remains intact, the risk of chasing strength has increased.
The model sees a credible bullish edge, with 68.6% upside probability, strong signal alignment, and reward/risk that remains meaningfully favorable.
Up probability is 68.6%, with predictability at 66% and signal agreement at 93%. Reversal risk is 12%, while reward/risk stands at 0.44. That suggests the directional case is supported by broad confirmation and still retains usable quality. At the same time, recent price behavior has shown failed reversal memory.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 18 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-08-17. The current price is 419.38, 5.98% above the estimated average cost of 395.71. An estimated 99.5% of recent positioning is below the current price, while 0.3% is above it. The peak-density price is 414.20. The largest concentrated cost region is 411.90 to 418.30 and contains 24.4% of the estimated distribution. The nearest region below the current price is 411.90 to 418.30.
Short Interest & Covering Risk for AMGN
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 22%)
Structure Analysis
AMGN Short positioning looks normal. Current days to cover is 5.2 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 19/100, DTC percentile 57%) despite a strong upward price move (20D return 15.2%) with short positioning continuing to expand and liquidity softening modestly (volume -13%).
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Price action is compressing (range is tightening), which can make breaks more sensitive. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-07-31 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.